Ontruzant Trastuzumab-Dttb Injection 150 mg Cancer Medicine **Refrigeration Required** (RX)

Ontruzant Trastuzumab-Dttb Injection 150 mg is a cancer medication used to treat certain types of breast, stomach, and gastroesophageal junction cancers that overexpress the HER2 protein. This injection contains the active ingredient trastuzumab-dttb and belongs to a class of drugs known as monoclonal antibodies. It works by binding to the HER2 protein on cancer cells and blocking their growth and division, ultimately leading to cell death. Ontruzant is biosimilar to the brand-name medication Herceptin, meaning it has been shown to be highly similar in effectiveness and safety profile. It is administered intravenously (into a vein) by a healthcare provider.

Ontruzant Trastuzumab-Dttb belongs to a class of medications known as monoclonal antibodies. It works by binding to a specific protein called HER2 (human epidermal growth factor receptor 2). HER2 is found in high levels on the surface of some cancer cells, including breast and gastric cancers. This protein helps cancer cells grow and spread.

By blocking the function of HER2, Ontruzant Trastuzumab-Dttb slows down the growth and spread of cancer cells. It also stimulates the body's immune system to attack and destroy the cancer cells.

In addition, Ontruzant Trastuzumab-Dttb may work with other chemotherapy medications to further inhibit the growth of cancer cells.

Overall, Ontruzant Trastuzumab-Dttb helps in treating cancers that overexpress HER2 protein, such as breast and gastric cancers.